SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).
Allen Lee Cohn
No relevant relationships to disclose
J. Randolph Hecht
Research Funding - Amgen
Shaker Dakhil
No relevant relationships to disclose
Mansoor N. Saleh
Consultant or Advisory Role - Amgen (U)
Bilal Piperdi
Consultant or Advisory Role - Amgen (U)
Vivian Jean M. Cline-Burkhardt
No relevant relationships to disclose
Ying Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
William Y. Go
Employment or Leadership Position - Amgen
Stock Ownership - Amgen